Exact Mass: 453.3467

Exact Mass Matches: 453.3467

Found 99 metabolites which its exact mass value is equals to given mass value 453.3467, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

10-Deoxymethymycin

10-Deoxymethymycin; YC-17

C25H43NO6 (453.309)


A macrolide antibiotic that is the 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexoside of 10-deoxymethynolide.

   

(11Z)-Eicoseneoylcarnitine

3-[(11Z)-Icos-11-enoyloxy]-4-(trimethylammonio)butanoic acid

C27H51NO4 (453.3818)


(11Z)-Eicoseneoylcarnitine is an acylcarnitine. More specifically, it is an cis-11-eicosenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z)-Eicoseneoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z)-Eicoseneoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(13Z)-Eicoseneoylcarnitine

3-(icos-13-enoyloxy)-4-(trimethylazaniumyl)butanoate

C27H51NO4 (453.3818)


(13Z)-Eicoseneoylcarnitine is an acylcarnitine. More specifically, it is an (13Z)-icos-13-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (13Z)-Eicoseneoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (13Z)-Eicoseneoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9Z)-Icos-9-enoylcarnitine

3-(icos-9-enoyloxy)-4-(trimethylazaniumyl)butanoate

C27H51NO4 (453.3818)


(9Z)-icos-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9Z)-icos-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z)-icos-9-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z)-icos-9-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Nervonoyl Serine

3-hydroxy-2-(tetracos-15-enamido)propanoic acid

C27H51NO4 (453.3818)


N-nervonoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Serine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(-)-Panclicin A

(-)-Panclicin A

C26H47NO5 (453.3454)


   
   
   
   

Lyngbyatoxin C

Lyngbyatoxin C

C27H39N3O3 (453.2991)


D009676 - Noxae > D011042 - Poisons > D008235 - Lyngbya Toxins D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins

   

2-oxo-teleocidin A1|JBIR-31

2-oxo-teleocidin A1|JBIR-31

C27H39N3O3 (453.2991)


   

Agelasimine A

Agelasimine A

C27H43N5O (453.3467)


   

PC(O-12:0/O-2:0)

3,5,9-Trioxa-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (1)-

C22H48NO6P (453.3219)


   

PC(O-13:0/O-1:0)[U]

3,5,9-Trioxa-4-phosphadocosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-, inner salt, 4-oxide

C22H48NO6P (453.3219)


   

PC(O-7:0/O-7:0)

3,5,9-Trioxa-4-phosphahexadecan-1-aminium, 7-(heptyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

C22H48NO6P (453.3219)


   

PC(O-7:0/O-7:0)[U]

3,5,9-Trioxa-4-phosphahexadecan-1-aminium, 7-(heptyloxy)-4-hydroxy-N,N,N-trimethyl-, inner salt, 4-oxide

C22H48NO6P (453.3219)


   

PC(O-14:0/0:0)

3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

C22H48NO6P (453.3219)


   

PC(O-14:0/0:0)[U]

3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide

C22H48NO6P (453.3219)


   

CAR 20:1

(11Z)-icoseneoylcarnitine;11-cis-eicoseneoylcarnitine;11-cis-icoseneoylcarnitine;3-[(11Z)-icos-11-enoyloxy]-4-(trimethylammonio)butanoate

C27H51NO4 (453.3818)


   

LPC O-14:0

1-tetradecyl-sn-glycero-3-phosphocholine

C22H48NO6P (453.3219)


   

Simvastatin ammonium salt

Simvastatin ammonium salt

C25H43NO6 (453.309)


Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1][2]. Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1][2].

   

dodecyl-dimethyl-(3-triethoxysilylpropyl)azanium,chloride

dodecyl-dimethyl-(3-triethoxysilylpropyl)azanium,chloride

C23H52ClNO3Si (453.3405)


   
   

tetrahexylazanium,perchlorate

tetrahexylazanium,perchlorate

C24H52ClNO4 (453.3585)


   

N-Octadecanoyl-L-phenylalanine sodiuM salt

N-Octadecanoyl-L-phenylalanine sodiuM salt

C27H44NNaO3 (453.3219)


   

Pentakis(diethylamino)niobium(V), 99.9 (Metals basis), Mixture of complexes

Pentakis(diethylamino)niobium(V), 99.9 (Metals basis), Mixture of complexes

C20H50N5Nb (453.313)


   
   
   

N-Nervonoyl Serine

N-Nervonoyl Serine

C27H51NO4 (453.3818)


   

(13Z)-Eicoseneoylcarnitine

(13Z)-Eicoseneoylcarnitine

C27H51NO4 (453.3818)


   

(9Z)-Icos-9-enoylcarnitine

(9Z)-Icos-9-enoylcarnitine

C27H51NO4 (453.3818)


   

Eicoseneoylcarnitine

Eicoseneoylcarnitine

C27H51NO4 (453.3818)


   

(2-Hydroxy-3-tetradecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(2-Hydroxy-3-tetradecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C22H48NO6P (453.3219)


   

NAGly 14:1/10:0

NAGly 14:1/10:0

C26H47NO5 (453.3454)


   

NAGly 13:1/11:0

NAGly 13:1/11:0

C26H47NO5 (453.3454)


   

NAGly 10:0/14:1

NAGly 10:0/14:1

C26H47NO5 (453.3454)


   

NAGly 11:0/13:1

NAGly 11:0/13:1

C26H47NO5 (453.3454)


   

2-Aminoethyl (3-heptadecoxy-2-hydroxypropyl) hydrogen phosphate

2-Aminoethyl (3-heptadecoxy-2-hydroxypropyl) hydrogen phosphate

C22H48NO6P (453.3219)


   
   

N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]dodecanamide

N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]dodecanamide

C27H51NO4 (453.3818)


   

(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]dodec-5-enamide

(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]dodec-5-enamide

C27H51NO4 (453.3818)


   

(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]tridec-8-enamide

(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]tridec-8-enamide

C27H51NO4 (453.3818)


   

N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tridecanamide

N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tridecanamide

C27H51NO4 (453.3818)


   

Cer 14:2;2O/13:0;(2OH)

Cer 14:2;2O/13:0;(2OH)

C27H51NO4 (453.3818)


   

Cer 14:1;2O/13:1;(3OH)

Cer 14:1;2O/13:1;(3OH)

C27H51NO4 (453.3818)


   

Cer 14:2;2O/13:0;(3OH)

Cer 14:2;2O/13:0;(3OH)

C27H51NO4 (453.3818)


   

Cer 15:1;2O/12:1;(3OH)

Cer 15:1;2O/12:1;(3OH)

C27H51NO4 (453.3818)


   

Cer 15:2;2O/12:0;(3OH)

Cer 15:2;2O/12:0;(3OH)

C27H51NO4 (453.3818)


   

Cer 15:2;2O/12:0;(2OH)

Cer 15:2;2O/12:0;(2OH)

C27H51NO4 (453.3818)


   

Cer 15:1;2O/12:1;(2OH)

Cer 15:1;2O/12:1;(2OH)

C27H51NO4 (453.3818)


   

Cer 14:1;2O/13:1;(2OH)

Cer 14:1;2O/13:1;(2OH)

C27H51NO4 (453.3818)


   

lysoDGTS 15:3

lysoDGTS 15:3

C25H43NO6 (453.309)


   

2-[[2-(Hexanoylamino)-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-(Hexanoylamino)-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[[2-(Butanoylamino)-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-(Butanoylamino)-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[Hydroxy-[3-hydroxy-2-(octanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium

2-[Hydroxy-[3-hydroxy-2-(octanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[Hydroxy-[3-hydroxy-2-(propanoylamino)tridecoxy]phosphoryl]oxyethyl-trimethylazanium

2-[Hydroxy-[3-hydroxy-2-(propanoylamino)tridecoxy]phosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[(2-Acetamido-3-hydroxytetradecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[(2-Acetamido-3-hydroxytetradecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium

2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)undecoxy]phosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

2-[[2-(Heptanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-(Heptanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C21H46N2O6P+ (453.3093)


   

(11Z)-eicoseneoylcarnitine

(11Z)-eicoseneoylcarnitine

C27H51NO4 (453.3818)


An O-acylcarnitine having (11Z)-eicoseneoyl as the acyl substituent.

   

1-tetradecyl-sn-glycero-3-phosphocholine

1-tetradecyl-sn-glycero-3-phosphocholine

C22H48NO6P (453.3219)


   

O-octadecadiendioylcarnitine

O-octadecadiendioylcarnitine

C25H43NO6 (453.309)


An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any octadecadiendioic acid with the hydroxy group of carnitine.

   

CarE(20:1)

CarE(20:1)

C27H51NO4 (453.3818)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

NA-2AAA 20:1(11Z)

NA-2AAA 20:1(11Z)

C26H47NO5 (453.3454)


   

NA-Asp 22:1(11Z)

NA-Asp 22:1(11Z)

C26H47NO5 (453.3454)


   

NA-Cit 19:1(9Z)

NA-Cit 19:1(9Z)

C25H47N3O4 (453.3566)


   

NA-Phe 20:3(8Z,11Z,14Z)

NA-Phe 20:3(8Z,11Z,14Z)

C29H43NO3 (453.3243)


   
   
   
   

Deoxy-methymycin

Deoxy-methymycin

C25H43NO6 (453.309)


   

Cer 14:2;O2/13:0;2OH

Cer 14:2;O2/13:0;2OH

C27H51NO4 (453.3818)


   

Cer 14:2;O2/13:0;3OH

Cer 14:2;O2/13:0;3OH

C27H51NO4 (453.3818)


   

Cer 14:2;O2/13:0;O

Cer 14:2;O2/13:0;O

C27H51NO4 (453.3818)


   

Cer 15:2;O2/12:0;2OH

Cer 15:2;O2/12:0;2OH

C27H51NO4 (453.3818)


   

Cer 15:2;O2/12:0;3OH

Cer 15:2;O2/12:0;3OH

C27H51NO4 (453.3818)


   

Cer 15:2;O2/12:0;O

Cer 15:2;O2/12:0;O

C27H51NO4 (453.3818)


   

Cer 16:2;O2/11:0;2OH

Cer 16:2;O2/11:0;2OH

C27H51NO4 (453.3818)


   

Cer 16:2;O2/11:0;3OH

Cer 16:2;O2/11:0;3OH

C27H51NO4 (453.3818)


   

Cer 16:2;O2/11:0;O

Cer 16:2;O2/11:0;O

C27H51NO4 (453.3818)


   

Cer 17:2;O2/10:0;2OH

Cer 17:2;O2/10:0;2OH

C27H51NO4 (453.3818)


   

Cer 17:2;O2/10:0;3OH

Cer 17:2;O2/10:0;3OH

C27H51NO4 (453.3818)


   

Cer 17:2;O2/10:0;O

Cer 17:2;O2/10:0;O

C27H51NO4 (453.3818)


   

ST 23:0;O4;Gly

ST 23:0;O4;Gly

C25H43NO6 (453.309)


   

(1r,10s,13s)-5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4(15),5,7,11-pentaene-2,11-diol

(1r,10s,13s)-5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4(15),5,7,11-pentaene-2,11-diol

C27H39N3O3 (453.2991)


   

(10s,13s)-5-[(3r,5e)-7-hydroxy-3,7-dimethylocta-1,5-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-5-[(3r,5e)-7-hydroxy-3,7-dimethylocta-1,5-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C27H39N3O3 (453.2991)


   

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-(8-methylnonyl)-4-oxooxetan-2-yl]nonan-2-yl]oxy}-1-oxopropan-2-yl]carboximidic acid

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-(8-methylnonyl)-4-oxooxetan-2-yl]nonan-2-yl]oxy}-1-oxopropan-2-yl]carboximidic acid

C26H47NO5 (453.3454)


   

(1s)-1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

(1s)-1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

C27H43N5O (453.3467)


   

(1s,2r,4as,8as)-1,2,5,5-tetramethyl-1-{3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl}-hexahydro-2h-naphthalen-4a-ol

(1s,2r,4as,8as)-1,2,5,5-tetramethyl-1-{3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl}-hexahydro-2h-naphthalen-4a-ol

C27H43N5O (453.3467)


   

1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

C27H43N5O (453.3467)


   

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-decyl-4-oxooxetan-2-yl]nonan-2-yl]oxy}-1-oxopropan-2-yl]carboximidic acid

n-[(2s)-1-{[(2s)-1-[(2s,3s)-3-decyl-4-oxooxetan-2-yl]nonan-2-yl]oxy}-1-oxopropan-2-yl]carboximidic acid

C26H47NO5 (453.3454)


   

5-(6-hydroxy-3,7-dimethylocta-1,7-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

5-(6-hydroxy-3,7-dimethylocta-1,7-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C27H39N3O3 (453.2991)


   

(2-{[(2r)-2-hydroxy-3-(tetradecyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

(2-{[(2r)-2-hydroxy-3-(tetradecyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium

C22H48NO6P (453.3219)


   

1,3-dimethyl-6-oxo-7-[(2e,6e,11e)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-2h-purin-2-yl

1,3-dimethyl-6-oxo-7-[(2e,6e,11e)-3,7,11,15-tetramethyl-13-oxohexadeca-2,6,11-trien-1-yl]-2h-purin-2-yl

C27H41N4O2 (453.3229)


   

(10s,13s)-5-[(3r)-6-hydroxy-3,7-dimethylocta-1,7-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-5-[(3r)-6-hydroxy-3,7-dimethylocta-1,7-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C27H39N3O3 (453.2991)


   

5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4(15),5,7,11-pentaene-2,11-diol

5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4(15),5,7,11-pentaene-2,11-diol

C27H39N3O3 (453.2991)


   

(1s,2r,4as,8as)-1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[(6e)-3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

(1s,2r,4as,8as)-1,2,5,5-tetramethyl-1-[(3e)-3-methyl-5-[(6e)-3-methyl-6-(methylimino)purin-7-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalen-4a-ol

C27H43N5O (453.3467)